Advice
in the absence of a submission from the holder of the marketing authorisation
quetiapine (Seroquel XL®) is not recommended for use within NHS Scotland.
Indication: Add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice38KB (PDF)
Medicine details
- Medicine name:
- quetiapine (Seroquel XL)
- SMC ID:
- 744/11
- Indication:
- Add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD)
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Central nervous system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 10 October 2011